Cancer cell-derived 12(S)-HETE signals via 12-HETE receptor, RHO, ROCK and MLC2 to induce lymph endothelial barrier breaching

Cancer cell-derived 12(S)-HETE signals via 12-HETE receptor, RHO, ROCK and MLC2 to induce lymph endothelial barrier breaching

British Journal of Cancer advance online publication, June 30 2016. doi:10.1038/bjc.2016.201

Authors: Chi Huu Nguyen, Serena Stadler, Stefan Brenner, Nicole Huttary, Sigurd Krieger, Walter Jäger, Helmut Dolznig & Georg Krupitza

29cdXac

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/2945XV8
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

Advertisements
Cancer cell-derived 12(S)-HETE signals via 12-HETE receptor, RHO, ROCK and MLC2 to induce lymph endothelial barrier breaching

News Progression-free survival with regorafenib in gastric cancer

fx1.sml

The oral multikinase inhibitor regorafenib improves progression-free survival for patients with refractory advanced gastric adenocarcinoma, according to new research by Nick Pavlakis (University of Sydney, Sydney, NSW, Australia) and colleagues. The multinational, randomised phase 2 trial assessed 147 patients with gastric adenocarcinoma who had previous undergone chemotherapy. 97 patients were randomly assigned to supportive care plus regorafenib, and 50 patients were assigned to supportive care plus placebo.

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/298DUX0
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

News Progression-free survival with regorafenib in gastric cancer

News Transoral robotic surgery for oropharyngeal cancer

bestscience_banner_287x140.jpg

Findings from a retrospective, stage-matched cohort study have shown that transoral robotic surgery for treatment of patients with oropharyngeal squamous cell carcinoma provides similar survival with significantly less morbidity than treatment with traditional non-surgical therapy such as radiotherapy or chemoradiotherapy.

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/298E7cH
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

News Transoral robotic surgery for oropharyngeal cancer

The pattern of prognostic and risk indicators among women with breast cancer undergoing modified radical mastectomy in Dar es Salaam, Tanzania

Breast cancer is the commonest female malignancy globally and the second (after uterine cervix) in sub-Saharan Africa including Tanzania. Prognostic indicators reportedly influence post-mastectomy adjuvant the…

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/29ha6ei
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

The pattern of prognostic and risk indicators among women with breast cancer undergoing modified radical mastectomy in Dar es Salaam, Tanzania

From palliative therapy to prolongation of survival: 223RaCl2 in the treatment of bone metastases

Patients with hormone-refractory prostate cancer often have multiple bone metastases. The resulting bone pain is associated with reduced life quality, increased cost of therapy and impairment of overall survival. Trials with bone-targeting β-emitters have mostly showed an effect on alleviation of bone pain along with prolongation in survival, documented in only a limited number of patients. A randomized phase III trial (ALSYMPCA) using the α-emitter 223RaCl2 (Xofigo®) showed for the first time, a longer overall survival of 3.6 months in treated patients as a sign of an antitumor effect. The time to first skeletal-related events was also significantly longer in the therapy group compared with placebo. Because of the short range of α-emitter, the bone marrow toxicity of radium therapy is low, and so this radionuclide could also be a candidate for combination with chemotherapy. The elimination of 223RaCl2 is mainly through the gastrointestinal tract and side effects are mainly in this area. The procedure is similar to treatment with other bone-seeking agents and consists of six administrations of 50 kBq/kg bodyweight Xofigo®, repeated every 4 weeks. At present Xofigo® is only approved for hormone-refractory prostate cancer.

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/295PNej
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

From palliative therapy to prolongation of survival: 223RaCl2 in the treatment of bone metastases

Differences between invasive lobular and invasive ductal carcinoma of the breast: results and therapeutic implications

Invasive lobular carcinoma (ILC) is the second most common histologic subtype of breast cancer (BC): ILC differs from invasive ductal carcinoma (IDC) in its clinicopathological characteristics and responsiveness to systemic therapy. From the clinical standpoint, data suggest that ILC derives a distinct benefit from systemic therapy compared to IDC. In addition, comprehensive molecular analyses have been reported for ILCs, confirming that these tumors have specific genomic profiles compared to IDC. Despite these differences, clinical trials and practical clinical guidelines tend to treat BC as a single entity. Here we discuss these clinical and molecular data and their therapeutic implications.

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/29eRwBK
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

Differences between invasive lobular and invasive ductal carcinoma of the breast: results and therapeutic implications